Wall Street Analyst Downgrade Coherus Biosciences Inc [CHRS]. What else is Wall St. saying

Coherus Biosciences Inc [NASDAQ: CHRS] closed the trading session at $1.72 on 11/13/23. The day’s price range saw the stock hit a low of $1.52, while the highest price level was $1.73. The company report on November 6, 2023 at 4:07 PM that Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights.

– Net revenue rose 27% from prior quarter to $74.6 million –– CIMERLI® net sales increased 50% to $40 million compared to prior quarter –– LOQTORZI™ now approved with launch planned for the first quarter of 2024 –– Conference call today at 5:00 p.m. Eastern Time –.

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.


Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended September 30, 2023, and recent business highlights:.

The stocks have a year to date performance of -78.28 percent and weekly performance of -51.41 percent. The stock has been moved at -64.83 percent over the last six months. The stock has performed -54.86 percent around the most recent 30 days and changed -61.52 percent over the most recent 3-months.

If compared to the average trading volume of 3.80M shares, CHRS reached to a volume of 7573825 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Coherus Biosciences Inc [CHRS]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CHRS shares is $10.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CHRS stock is a recommendation set at 1.88. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Maxim Group have made an estimate for Coherus Biosciences Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on November 08, 2023.

The Average True Range (ATR) for Coherus Biosciences Inc is set at 0.38, with the Price to Sales ratio for CHRS stock in the period of the last 12 months amounting to 0.91.

CHRS stock trade performance evaluation

Coherus Biosciences Inc [CHRS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -51.41. With this latest performance, CHRS shares dropped by -54.86% in over the last four-week period, additionally sinking by -64.83% over the last 6 months – not to mention a drop of -78.03% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CHRS stock in for the last two-week period is set at 29.50, with the RSI for the last a single of trading hit 26.86, and the three-weeks RSI is set at 31.72 for Coherus Biosciences Inc [CHRS]. The present Moving Average for the last 50 days of trading for this stock 3.6905, while it was recorded at 1.8820 for the last single week of trading, and 5.3398 for the last 200 days.

Coherus Biosciences Inc [CHRS]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Coherus Biosciences Inc [CHRS] shares currently have an operating margin of -121.72 and a Gross Margin at +65.04. Coherus Biosciences Inc’s Net Margin is presently recorded at -138.24.

Return on Total Capital for CHRS is now -59.76, given the latest momentum, and Return on Invested Capital for the company is -68.49. Additionally, CHRS Total Debt to Total Capital is recorded at 140.06, with Total Debt to Total Assets ending up at 99.91.

Reflecting on the efficiency of the workforce at the company, Coherus Biosciences Inc [CHRS] managed to generate an average of -$812,685 per employee. Receivables Turnover for the company is 1.81 with a Total Asset Turnover recorded at a value of 0.36.Coherus Biosciences Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.58 and a Current Ratio set at 1.85.

Coherus Biosciences Inc [CHRS]: Institutional Ownership

The top three institutional holders of CHRS stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in CHRS stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in CHRS stock with ownership which is approximately 5.7994%.